Lord's Mark Industries Limited has submitted a regulatory disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company announced the successful completion of Phase I of its expansion plan at its Silvassa facility.
The expansion was completed nearly three months ahead of its originally committed timeline of December 2026. As a result of this expansion, the company's surgical and orthopaedic product portfolio has significantly expanded from 36 Stock Keeping Units (SKUs) to 54 SKUs, representing the addition of 18 new products.
The newly expanded production line is scheduled to commence commercial operations from October 11, 2026. Regarding regulatory status, the company's existing portfolio of 36 surgical and orthopaedic products already holds approval from the US Food and Drug Administration (US FDA). The 18 newly introduced SKUs are currently progressing through the US FDA approval process and are anticipated to receive clearance before December 2026.
The company states that this strategic expansion reinforces its manufacturing capabilities, broadens its market reach across domestic and international healthcare ecosystems, and supports its long-term vision of becoming a recognized global player in the medical devices industry.